Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets
The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.
Abstract
BH3 mimetics are a new class of proapo-ptotic anticancer agents that have shown considerable promise in preclinical animal models and early-stage human trials. These agents act by inhibiting the pro-survival function of one or more Bcl-2–related proteins. Agents that inhibit Bcl-xL induce rapid platelet death that leads to thrombocytopenia; however, their impact on the function of residual circulating platelets remains unclear. In this study, we demonstrate that the BH3 mimetics, ABT-737 or ABT-263, induce a time- and dose-dependent decrease in platelet adhesive function that correlates with ectodomain shedding of the major platelet adhesion receptors, glycoprotein Ibα and glycoprotein VI, and functional down-regulation of integrin αIIbβ3. Analysis of platelets from mice treated with higher doses of BH3 mimetics revealed the presence of a subpopulation of circulating platelets undergoing cell death that have impaired activation responses to soluble agonists. Functional analysis of platelets by intravital microscopy revealed a time-dependent defect in platelet aggregation at sites of vascular injury that correlated with an increase in tail bleeding time. Overall, these studies demonstrate that Bcl-xL–inhibitory BH3 mimetics not only induce thrombocytopenia but also a transient thrombocytopathy that can undermine the hemostatic function of platelets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, targeting BCL-XL with conventional inhibitors causes severe thrombocytopenia, limiting their clinical use [5–7].”
From BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers (2022) · cites this paper as [7]
In the citing paper
“However, several other studies indicated that ABT263 and other Bcl-xL-inhibitory BH3 mimetics induced thrombocytopenia and a transient thrombocytopathy, which could impair the haemostatic function of platelets.33,34”
From The costs and benefits of senotherapeutics for human health (2022) · cites this paper as [33]
In the citing paper
“Since platelets depend on BCL-XL for survival, BCL-XL inhibition by the dual BCL-XL/BCL-2 inhibitor ABT263 or monoselective BCL-XL inhibitors (A1155463 or A1331852) causes severe platelet toxicity [81, 90], which limits the clinical development of these inhibitors as safer anticancer therapeutics.”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [90]
Citations
Cites
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
Self-citationCaspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing
Sebbagh, M., Renvoizé, C., Hamelin, J., Riché, N., Bertoglio, J., & Bréard, J. (2001) · Nature Cell Biology · doi:10.1038/35070019 · Cited by 915
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Oncogenic PI3K deregulates transcription and translation
Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1753 · Cited by 798
PI 3-kinase p110β: a new target for antithrombotic therapy
Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 580
Self-citation
Cited by
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
“Unfortunately, ABT263 has possible adverse effects; specifically, it is toxic to platelets and induces transient thrombocytopenia and thrombopathy.(569) Other senolytic drugs, such as ABT-199 (a Bcl-2 inhibitor) and ABT737 (a Bcl-2, Bcl-xL, and Bcl-w inhibitor), can also remove senescent β-cells.”
BackgroundBaar, M. P., Brandt, R. M. C., Putavet, D. A., Klein, J. D. D., Derks, K. W. J., Bourgeois, B. R. M., Stryeck, S., Rijksen, Y., van Willigenburg, H., Feijtel, D. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.031 · Cited by 1,454
“A limitation to the therapeutic potential of the senolytic panBCL inhibitors ABT-263/ABT-737 is their tendency to cause severe thrombocytopenia (Schoenwaelder et al., 2011).”
BackgroundSelective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Pan, R., Hogdal, L. J., Benito, J. M., Bucci, D., Han, L., Borthakur, G., Cortes, J., DeAngelo, D. J., Debose, L., Mu, H., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0609 · Cited by 735
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K.-S., Kaniskan, H. Ü., Xiong, Y., & Jin, J. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00365-x · Cited by 632
Metadata
- Authors
- Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., Andrews, R. K., Mason, K. D., Salem, H. H., Huang, D. C. S., Kile, B. T., Roberts, A. W., & Jackson, S. P.
- Affiliations
- Monash University (AU)
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Schoenwaelder, Simone M.
- Jarman, Kate E.
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2011-08-11
- Volume
- 118
- Issue
- 6
- Pages
- 1663-1674
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2031641885
- Cited by
- 351
- References
- 48
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 39 · 2023: 30 · 2022: 35 · 2021: 25 · 2020: 25 · 2019: 14 · 2018: 23 · 2017: 18 · 2016: 19 · 2015: 17 · 2014: 18 · 2013: 18 · 2012: 19
- FWCI
- 12.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Abbott Fund
- Genentech
- Topics
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- BH3 mimetics, BCL-XL inhibition, ABT-737, navitoclax, platelet function, platelet disorders, platelet adhesion, GPIbα, glycoprotein VI, integrin αIIbβ3, platelet aggregation, hemostasis, thrombocytopenia, vascular injury
- MeSH terms
- Aniline Compounds, Animals, Biphenyl Compounds, Blood Platelets, Collagen, Dose-Response Relationship, Drug, Hemostasis, Membrane Glycoproteins, Mice, Inbred C57BL, Microscopy, Electron, Scanning, Nitrophenols, Phosphatidylserines, Piperazines, Platelet Adhesiveness, Platelet Aggregation, Platelet Count, Platelet Membrane Glycoproteins, Sulfonamides, Thrombocytopenia, Time Factors, Blotting, Western, Down-Regulation, Apoptosis, Platelet Glycoprotein GPIb-IX Complex, Platelet Glycoprotein GPIIb-IIIa Complex, bcl-X Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. https://app.cochat.ai/papers/10.1182/blood-2011-04-347849
- The paper
- Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., Andrews, R. K., Mason, K. D., Salem, H. H., Huang, D. C. S., Kile, B. T., Roberts, A. W., & Jackson, S. P. (2011). Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood. https://doi.org/10.1182/blood-2011-04-347849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.